AMP-Activated Protein Kinase α 2 Isoform Suppression in Primary Breast Cancer Alters AMPK Growth Control and Apoptotic Signaling

Genes and Cancer

Volumn 4, Issue 1-2, 2013, Pages 3-14

  Fox, Melissa M ^a   Phoenix, Kathryn N ^a   Kopsiaftis, Stavros G ^a   Claffey, Kevin P ^a  

^a UNIVERSITY OF CONNECTICUT HEALTH CENTER   (United States)

Author keywords

AMPK; apoptosis; breast cancer; cell cycle arrest; p53

Indexed keywords

AMP ACTIVATED PROTEIN KINASE ALPHA 1; AMP ACTIVATED PROTEIN KINASE ALPHA 2; CYCLIN D1; GLUCOSE; GREEN FLUORESCENT PROTEIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE KINASE; ISOPROTEIN; MAMMALIAN TARGET OF RAPAMYCIN; PROTEIN P53; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; BREAST CANCER; BREAST EPITHELIUM; CANCER CELL; CANCER GROWTH; CELL ASSAY; CELL GROWTH; CELL METABOLISM; CELL PROLIFERATION; CELL STRAIN MCF 7; CELL STRESS; CONTROLLED STUDY; ENZYME ACTIVITY; ENZYME REPRESSION; G1 PHASE CELL CYCLE CHECKPOINT; GENE SILENCING; GENETIC TRANSFECTION; GLUCOSE METABOLISM; GROWTH INHIBITION; GROWTH REGULATION; HUMAN; HUMAN CELL; METABOLIC STRESS; MOUSE; NONHUMAN; PRIMARY TUMOR; PRIORITY JOURNAL; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION; TUMOR XENOGRAFT;

EID: 84887483102     PISSN: 19476019     EISSN: 19476027     Source Type: Journal    
DOI: 10.1177/1947601913486346     Document Type: Article

References (56)

1. Hardie DG.AMP-activated protein kinase: an energy sensor that regulates all aspects of cell function.Genes Dev. 2011;25:1895-908.
2. Shaw RJ,Kosmatka M,Bardeesy N, et al.The tumor suppressor LKB1 kinase directly activates AMP-activated kinase and regulates apoptosis in response to energy stress.Proc Natl Acad Sci U S A. 2004;101:3329-35.
3. Stein SC,Woods A,Jones NA,Davison MD,Carling D.The regulation of AMP-activated protein kinase by phosphorylation.Biochem J. 2000;345:437-43.
4. Hardie DG.AMPK: a key regulator of energy balance in the single cell and the whole organism.Int J Obes. 2008;32:S7-12.
5. Kahn BB,Alquier T,Carling D,Hardie DG.AMP-activated protein kinase: ancient energy gauge provides clues to modern understanding of metabolism.Cell Metab. 2005;1:15-25.
6. Neurath KM,Keough MP,Mikkelsen T,Claffey KP.AMP-dependent protein kinase alpha 2 isoform promotes hypoxia-induced VEGF expression in human glioblastoma.Glia. 2006;53:733-43.
7. Jones RG,Plas DR,Kubek S, et al.AMP-activated protein kinase induces a p53-dependent metabolic checkpoint.Mol Cell. 2005;18:283-93.
8. Okoshi R,Ozaki T,Yamamoto H, et al.Activation of AMP-activated protein kinase induces p53-dependent apoptotic cell death in response to energetic stress.J Biol Chem. 2008;283:3979-87.
9. Thoreen CC,Sabatini DM.AMPK and p53 help cells through lean times.Cell Metab. 2005;1:287-8.
10. Kim J,Kundu M,Viollet B,Guan K-L.AMPK and mTOR regulate autophagy through direct phosphorylation of Ulk1.Nat Cell Biol. 2011;13:132-41.
11. Lee JW,Park S,Takahashi Y,Wang H-G.The association of AMPK with ULK1 regulates autophagy.PLoS One. 2010;5:e15394.
12. Luo Z,Zang M,Guo W.AMPK as a metabolic tumor suppressor: control of metabolism and cell growth.Future Oncol. 2010;6:457-70.
13. Martin-Belmonte F,Perez-Moreno M.Epithelial cell polarity, stem cells and cancer.Nat Rev Cancer. 2012;12:23-38.
14. Vazquez-Martin A,Oliveras-Ferraros C,Menendez JA, et al.The active form of the metabolic sensor: AMP-activated protein kinase (AMPK) directly binds the mitotic apparatus and travels from centrosomes to the spindle midzone during mitosis and cytokinesis.Cell Cycle. 2009;8:2385-98.
15. Lee JH,Koh H,Kim M, et al.Energy-dependent regulation of cell structure by AMP-activated protein kinase.Nature. 2007;447:1017-20.
16. Khanal P,Kim G,Yun HJ,Cho H-G,Choi HS.The prolyl isomerase Pin1 interacts with and downregulates the activity of AMPK leading to induction of tumorigenicity of hepatocarcinoma cells.Mol Carcinog. 2012;:.
17. Zakikhani M,Dowling R,Fantus IG,Sonenberg N,Pollak M.Metformin is an AMP kinase-dependent growth inhibitor for breast cancer cells.Cancer Res. 2006;66:10269-73.
18. Gonzalez-Angulo AM,Meric-Bernstam F.Metformin: a therapeutic opportunity in breast cancer.Clin Cancer Res. 2010;16:1695-700.
19. Evans JMM,Donnelly LA,Emslie-Smith AM,Alessi DR,Morris AD.Metformin and reduced risk of cancer in diabetic patients.BMJ. 2005;330:1304-5.
20. Bodmer M,Meier C,Krähenbühl S,Jick SS,Meier CR.Long-term metformin use is associated with decreased risk of breast cancer.Diabetes Care. 2010;33:1304-8.
21. Bosco JLF,Antonsen S,Sørensen HT,Pedersen L,Lash TL.Metformin and incident breast cancer among diabetic women: a population-based case-control study in Denmark.Cancer Epidemiol Biomarkers Prev. 2011;20:101-11.
22. Donadon V,Balbi M,Mas MD,Casarin P,Zanette G.Metformin and reduced risk of hepatocellular carcinoma in diabetic patients with chronic liver disease.Liver Int. 2010;30:750-8.
23. Monami M,Colombi C,Balzi D, et al.Metformin and cancer occurrence in insulin-treated type 2 diabetic patients.Diabetes Care. 2011;34:129-31.
24. Zhang Z-J,Zheng Z-J,Kan H, et al.Reduced risk of colorectal cancer with metformin therapy in patients with type 2 diabetes.Diabetes Care. 2011;34:2323-8.
25. Goodwin PJ,Ligibel JA,Stambolic V.Metformin in breast cancer: time for action.J Clin Oncol. 2009;27:3271-3.
26. Hadad S,Iwamoto T,Jordan L, et al.Evidence for biological effects of metformin in operable breast cancer: a pre-operative, window-of-opportunity, randomized trial.Breast Cancer Res Treat. 2011;128:783-94.
27. Hadad SM,Baker L,Quinlan PR, et al.Histological evaluation of AMPK signalling in primary breast cancer.BMC Cancer. 2009;9:307.
28. Liu B,Fan Z,Edgerton SM, et al.Metformin induces unique biological and molecular responses in triple negative breast cancer cells.Cell Cycle. 2009;8:2031-40.
29. Zhuang Y,Miskimins WK.Cell cycle arrest in metformin treated breast cancer cells involves activation of AMPK, downregulation of cyclin D1, and requires p27Kip1 or p21Cip1.J Mol Signal. 2008;3:18.
30. Bartek J,Iggo R,Gannon J,Lane DP.Genetic and immunochemical analysis of mutant p53 in human breast cancer cell lines.Oncogene. 1990;5:893-9.
31. Ben Sahra I,Laurent K,Loubat A, et al.The antidiabetic drug metformin exerts an antitumoral effect in vitro and in vivo through a decrease of cyclin D1 level.Oncogene. 2008;27:3576-86.
32. Zhuang Y,Miskimins WK.Metformin induces both caspase-dependent and poly(ADP-ribose) polymerase-dependent cell death in breast cancer cells.Mol Cancer Res. 2011;9:603-15.
33. Zhuang Y,Miskimins WK,Turashvili G, et al.Cell cycle arrest in metformin treated breast cancer cells involves activation of AMPK, downregulation of cyclin D1, and requires p27Kip1 or p21Cip1.J Mol Signal. 2008;3:18.
34. Guo D,Hildebrandt IJ,Prins RM, et al.The AMPK agonist AICAR inhibits the growth of EGFRvIII-expressing glioblastomas by inhibiting lipogenesis.Proc Natl Acad Sci U S A. 2009;106:12932-7.
35. Rattan R,Giri S,Singh AK,Singh I.5-aminoimidazole-4-carboxamide-1-β-D-ribofuranoside inhibits cancer cell proliferation in vitro and in vivo via AMP-activated protein kinase.J Biol Chem. 2005;280:39582-93.
36. Su R-Y,Chao Y,Chen T-Y,Huang D-Y,Lin W-W.5-aminoimidazole-4-carboxamide riboside sensitizes TRAIL- and TNFα-induced cytotoxicity in colon cancer cells through AMP-activated protein kinase signaling.Mol Cancer Ther. 2007;6:1562-71.
37. Woodard J,Joshi S,Viollet B,Hay N,Platanias LC.AMPK as a therapeutic target in renal cell carcinoma.Cancer Biol Ther. 2010;10:1168-77.
38. Imamura K,Ogura T,Kishimoto A,Kaminishi M,Esumi H.Cell cycle regulation via p53 phosphorylation by a 5'-AMP activated protein kinase activator, 5-aminoimidazole-4-carboxamide-1-[beta]-ribofuranoside, in a human hepatocellular carcinoma cell line.Biochem Biophys Res Commun. 2001;287:562-7.
39. Zuckerman V,Wolyniec K,Sionov RV,Haupt S,Haupt Y.Tumour suppression by p53: the importance of apoptosis and cellular senescence.J Pathol. 2009;219:3-15.
40. Rattan R,Giri S,Hartmann LC,Shridhar V.Metformin attenuates ovarian cancer cell growth in an AMP-kinase dispensable manner.J Cell Mol Med. 2011;15:166-78.
41. Buzzai M,Jones RG,Amaravadi RK, et al.Systemic treatment with the antidiabetic drug metformin selectively impairs p53-deficient tumor cell growth.Cancer Res. 2007;67:6745-52.
42. Fenton H,Carlile B,Montgomery EA, et al.LKB1 protein expression in human breast cancer.Appl Immunohistochem Mol Morphol. 2006;14:146-53.
43. Kan Z,Jaiswal BS,Stinson J, et al.Diverse somatic mutation patterns and pathway alterations in human cancers.Nature. 2010;466:869-73.
44. Glück S,Ross J,Royce M, et al.TP53 genomics predict higher clinical and pathologic tumor response in operable early-stage breast cancer treated with docetaxel-capecitabine ± trastuzumab.Breast Cancer Res Treat. 2012;132:781-91.
45. Richardson AL,Wang ZC,De Nicolo A, et al.X chromosomal abnormalities in basal-like human breast cancer.Cancer Cell. 2006;9:121-32.
46. Turashvili G,Bouchal J,Baumforth K, et al.Novel markers for differentiation of lobular and ductal invasive breast carcinomas by laser microdissection and microarray analysis.BMC Cancer. 2007;7:55.
47. Kim YH,Liang H,Liu X, et al.AMPKα modulation in cancer progression: multilayer integrative analysis of the whole transcriptome in Asian gastric cancer.Cancer Res. 2012;72:2512-21.
48. Zhou J,Huang W,Tao R, et al.Inactivation of AMPK alters gene expression and promotes growth of prostate cancer cells.Oncogene. 2009;28:1993-2002.
49. Woods A,Salt I,Scott J,Hardie DG,Carling D.The α1 and α2 isoforms of the AMP-activated protein kinase have similar activities in rat liver but exhibit differences in substrate specificity in vitro.FEBS Lett. 1996;397:347-51.
50. Michell BJ,Stapleton D,Mitchelhill KI, et al.Isoform-specific purification and substrate specificity of the 5′-AMP-activated protein kinase.J Biol Chem. 1996;271:28445-50.
51. Phoenix KN,Devarakonda CV,Fox MM,Stevens LE,Claffey KP.AMPKalpha2 suppresses murine embryonic fibroblast transformation and tumorigenesis.Genes Cancer. 2012;3:51-62.
52. Cohen B,Shimizu M,Izrailit J, et al.Cyclin D1 is a direct target of JAG1-mediated Notch signaling in breast cancer.Breast Cancer Res Treat. 2010;123:113-24.
53. Lavoie JN,L'Allemain G,Brunet A,Müller R,Pouysségur J.Cyclin D1 expression is regulated positively by the p42/p44MAPK and negatively by the p38/HOGMAPK pathway.J Biol Chem. 1996;271:20608-16.
54. Saitoh M,Ohmichi M,Takahashi K, et al.Medroxyprogesterone acetate induces cell proliferation through up-regulation of cyclin D1 expression via phosphatidylinositol 3-kinase/Akt/nuclear factor-κB cascade in human breast cancer cells.Endocrinology. 2005;146:4917-25.
55. Torricelli C,Fortino V,Capurro E, et al.Rottlerin inhibits the nuclear factor κB/Cyclin-D1 cascade in MCF-7 breast cancer cells.Life Sci. 2008;82:638-43.
56. Phoenix K,Vumbaca F,Claffey K.Therapeutic metformin/AMPK activation promotes the angiogenic phenotype in the ERα negative MDA-MB-435 breast cancer model.Breast Cancer Res Treat. 2009;113:101-11.